Literature DB >> 24115193

Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.

Shen-Ju Gou1, Jun Yuan, Chen Wang, Ming-Hui Zhao, Min Chen.   

Abstract

BACKGROUND AND OBJECTIVES: Previous study revealed that complement activation products of the alternative pathway could be detected in renal specimens of human ANCA-associated vasculitis. The current study aimed to investigate the clinical and pathologic significance of complement activation products in the urine and kidneys of patients with ANCA-associated vasculitis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Renal biopsy specimens from 29 patients with ANCA-associated vasculitis diagnosed at Peking University First Hospital from January of 2008 to December of 2010 were randomly collected. Urine samples from 27 of 29 patients in active stage and 22 ANCA-associated vasculitis patients in complete remission who were independent of the above-mentioned 29 patients were collected. Urine samples from 28 patients with lupus nephritis and 25 healthy individuals were also collected. The renal deposition of Bb, C3d, and C5b-9 were detected by immunohistochemistry. The urinary levels of Bb, C3a, C5a, and soluble C5b-9 were determined by ELISA.
RESULTS: The deposition, measured by the mean optical density of Bb, which is an alternative complement pathway marker, in glomeruli correlated with the proportion of total crescents (r=0.50, P=0.006), the extent of interstitial infiltrate (r=0.59, P=0.001), interstitial fibrosis (r=0.45, P=0.01), and tubular atrophy (r=0.55, P=0.002), whereas it correlated inversely with the proportion of normal glomeruli (r=-0.49, P=0.008). The urinary levels of Bb, C3a, C5a, and soluble C5b-9 were all significantly higher in active compared with remission stage. The urinary levels of Bb in patients with active ANCA-associated vasculitis correlated with the serum creatinine (r=0.56, P=0.002) and correlated inversely with the proportion of normal glomeruli in renal specimens (r=-0.49, P=0.009).
CONCLUSIONS: The present study provides additional evidence that complement activation through the alternative pathway occurred in the development of ANCA-associated vasculitis. The renal deposition of Bb and urinary Bb levels were associated with the severity of renal injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24115193      PMCID: PMC3817906          DOI: 10.2215/CJN.02790313

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

Review 1.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

2.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  ANCA small-vessel vasculitis.

Authors:  R J Falk; J C Jennette
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

5.  The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis.

Authors:  Y Morita; A Nomura; Y Yuzawa; K Nishikawa; N Hotta; F Shimizu; S Matsuo
Journal:  J Am Soc Nephrol       Date:  1997-09       Impact factor: 10.121

Review 6.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

7.  Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.

Authors:  D Huugen; A van Esch; H Xiao; C J Peutz-Kootstra; W A Buurman; J W Cohen Tervaert; J C Jennette; P Heeringa
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

8.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.

Authors:  Adrian Schreiber; Hong Xiao; J Charles Jennette; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

10.  Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis.

Authors:  Min Chen; Guang-Qun Xing; Feng Yu; Gang Liu; Ming-Hui Zhao
Journal:  Nephrol Dial Transplant       Date:  2008-10-21       Impact factor: 5.992

View more
  54 in total

Review 1.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

Review 2.  Complement in ANCA-associated vasculitis: mechanisms and implications for management.

Authors:  Min Chen; David R W Jayne; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-03-20       Impact factor: 28.314

Review 3.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

4.  Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  L Cheng; S-J Gou; H-Y Qiu; L Ma; P Fu
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

Review 5.  The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.

Authors:  G Trivioli; A Vaglio
Journal:  Clin Exp Immunol       Date:  2020-10-05       Impact factor: 4.330

Review 6.  Overview of the Pathogenesis of ANCA-Associated Vasculitis.

Authors:  Hong Xiao; Peiqi Hu; Ronald J Falk; J Charles Jennette
Journal:  Kidney Dis (Basel)       Date:  2015-12-03

Review 7.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

8.  The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis.

Authors:  S Moiseev; J M Lee; A Zykova; N Bulanov; P Novikov; E Gitel; M Bulanova; E Safonova; J I Shin; A Kronbichler; D R W Jayne
Journal:  Clin Exp Immunol       Date:  2020-09-15       Impact factor: 4.330

Review 9.  The role of complement in kidney disease.

Authors:  Jamie Willows; Matthew Brown; Neil S Sheerin
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

10.  Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.

Authors:  Lucio Manenti; Augusto Vaglio; Elisa Gnappi; Umberto Maggiore; Landino Allegri; Marco Allinovi; Maria L Urban; Marco Delsante; Maricla Galetti; Maria Nicastro; Francesco P Pilato; Carlo Buzio
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-05       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.